{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:08:21Z","timestamp":1783534101671,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":2583,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.fertnstert.2015.02.011","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T19:31:55Z","timestamp":1426534315000},"page":"1305-1312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers"],"prefix":"10.1016","volume":"103","author":[{"given":"Tamar","family":"Perri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Lifshitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegal","family":"Sadetzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Oberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Meirow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Ben-Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Korach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2015.02.011_bib1","first-page":"11","article-title":"Cancer statistics","volume":"2013","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib4","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0511301103","article-title":"Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population","volume":"103","author":"Simchoni","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GRF.0b013e31824b4611","article-title":"Ovarian cancer: etiology, risk factors, and epidemiology","volume":"55","author":"Hunn","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/89.13.932","article-title":"Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer","volume":"89","author":"Schildkraut","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1126\/science.2136249","article-title":"Too many rodent carcinogens: mitogenesis increases mutagenesis","volume":"249","author":"Ames","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.2013.344","article-title":"Hormonal risk factors and invasive epithelial ovarian cancer risk by parity","volume":"109","author":"Bodelon","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/aje\/kwq264","article-title":"Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study","volume":"172","author":"Braem","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11864-009-0108-2","article-title":"Current understanding of risk factors for ovarian cancer","volume":"10","author":"Sueblinvong","year":"2009","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/aje\/kwn006","article-title":"Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women","volume":"167","author":"Moorman","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib12","first-page":"399","article-title":"Advances in the understanding of risk factors for ovarian cancer","volume":"50","author":"Bandera","year":"2005","journal-title":"J Reprod Med"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib13","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/ijc.23287","article-title":"Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis","volume":"122","author":"Jordan","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","article-title":"Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study","volume":"8","author":"McLaughlin","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM200107263450401","article-title":"Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation","volume":"345","author":"Modan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group","volume":"339","author":"Narod","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1\/2 Carrier Cohort Study","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib18","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.fertnstert.2012.12.029","article-title":"In\u00a0vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services","volume":"99","author":"Brinton","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0015-0282(16)58557-4","article-title":"Ovulation induction, infertility, and ovarian cancer risk","volume":"66","author":"Bristow","year":"1996","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.fertnstert.2005.08.061","article-title":"Induction of ovulation and ovarian cancer: a critical review of the literature","volume":"85","author":"Mahdavi","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-2003-39996","article-title":"Ovarian cancer and fertility medications: a critical appraisal","volume":"21","author":"Kashyap","year":"2003","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib23","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/sj.bjc.6605086","article-title":"Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort","volume":"100","author":"Silva Idos","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/aje\/kwn094","article-title":"Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women","volume":"168","author":"Jensen","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.fertnstert.2008.01.073","article-title":"Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden","volume":"91","author":"Sanner","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJM199409223311204","article-title":"Ovarian tumors in a cohort of infertile women","volume":"331","author":"Rossing","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/09513590.2012.705382","article-title":"Fertility drug use and risk of ovarian tumors: a debated clinical challenge","volume":"29","author":"Gadducci","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/aje\/kwn318","article-title":"Cancer risk after exposure to treatments for ovulation induction","volume":"169","author":"Calderon-Margalit","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/09513590701350341","article-title":"Ovulation induction treatment and risk of borderline ovarian tumors","volume":"23","author":"Cusid\u00f3","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/09513590.2012.671391","article-title":"Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up","volume":"28","author":"Lerner-Geva","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib31","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/1055-9965.EPI-12-0426","article-title":"Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study","volume":"21","author":"Kurta","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib32","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.fertnstert.2013.02.010","article-title":"Fertility drug use and the risk of ovarian tumors in infertile women: a case-control study","volume":"99","author":"Asante","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib33","first-page":"CD008215","article-title":"Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility","author":"Rizzuto","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-010-1217-0","article-title":"Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel","volume":"127","author":"Laitman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib35","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.fertnstert.2013.08.008","article-title":"Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort","volume":"100","author":"Trabert","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib36","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/oxfordjournals.aje.a116428","article-title":"Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group","volume":"136","author":"Harris","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/aje\/155.3.217","article-title":"Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies","volume":"155","author":"Ness","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib38","first-page":"1111","article-title":"Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study","volume":"19","author":"Kotsopoulos","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib39","first-page":"645","article-title":"Infertility and risk of fatal ovarian cancer in a prospective cohort of US women","volume":"9","author":"Rodriguez","year":"1998","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib40","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0015-0282(97)81431-8","article-title":"Infertility, fertility drugs, and invasive ovarian cancer: a case-control study","volume":"67","author":"Mosgaard","year":"1997","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10549-009-0394-1","article-title":"Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers","volume":"119","author":"Milne","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10689-009-9313-1","article-title":"Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain","volume":"9","author":"Sanz","year":"2010","journal-title":"Fam Cancer"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/humupd\/dmm012","article-title":"Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis","volume":"13","author":"Greiser","year":"2007","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib44","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the million women study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/13697137.2012.663818","article-title":"Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy\u2014a nationwide study","volume":"16","author":"Koskela-Niska","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jama.2009.1052","article-title":"Hormone therapy and ovarian cancer","volume":"302","author":"M\u00f8rch","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ygyno.2005.07.110","article-title":"Hormone replacement therapy and the risk of ovarian cancer in\u00a0BRCA1 and BRCA2 mutation carriers","volume":"100","author":"Kotsopoulos","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3109\/09513590.2010.487609","article-title":"Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy","volume":"26","author":"Gadducci","year":"2010","journal-title":"Gynecol Endocrinol"},{"issue":"11 Suppl 2","key":"10.1016\/j.fertnstert.2015.02.011_bib50","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1111\/IGC.0b013e3181f60d4d","article-title":"The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review","volume":"20","author":"Fishman","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2008.01.012","article-title":"A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with heterozygous BRCA mutations","volume":"109","author":"Folkins","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.fertnstert.2015.02.011_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.pgp.0000101083.35393.cd","article-title":"Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry","volume":"23","author":"Werness","year":"2004","journal-title":"Int J Gynecol Pathol"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028215001338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028215001338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:18:34Z","timestamp":1758010714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028215001338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0015028215001338"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2015.02.011","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2015.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}